Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
about
Approaches to preventative and therapeutic HIV vaccinesTowards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infectionHIV-1 antibodies from infection and vaccination: insights for guiding vaccine designVirological features associated with the development of broadly neutralizing antibodies to HIV-1Broad and potent neutralization of HIV-1 by a gp41-specific human antibodyMultidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class AntibodiesBroadly Neutralizing Antibodies for HIV EradicationHIV-1 gp120 as a therapeutic target: navigating a moving labyrinthSurvivors Remorse: antibody-mediated protection against HIV-1.Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune SystemHuman immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypesHIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus InfectionStrategies to guide the antibody affinity maturation processEffects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection.Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virusDistinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages.Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection.A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01.CD4 binding determinant mimicry for HIV vaccine design.Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicidesKey gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese DonorDetection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors.Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.Study of antibody repertoires to the CD4 binding site of gp120 of a Chinese HIV-1-infected elite neutralizer, using 454 sequencing and single-cell sorting.Persistence of VRC01-resistant HIV-1 during antiretroviral therapy.HIV antibodies for treatment of HIV infection.Potent In Vivo NK Cell-mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-bispecific and Hexavalent Broadly Neutralizing Fusion Protein.The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards.
P2860
Q26764851-ECAB71E5-352A-4920-B896-0DE50DB63D78Q27005830-A41205E1-1A88-4589-8DFD-058CFC899DEFQ27022055-168ADAF4-4C20-4E47-879A-6CCB7FC4AA92Q27025177-518C5D30-6CEC-478A-A297-5259415B45BEQ27675131-3DCC6E3D-0866-4CE1-9E9F-0AC3AD918D2AQ27679353-179B80D1-99A2-4FAB-B5F2-B7C31BF2C821Q28073939-DE13FE4B-287C-46D5-B1FD-40F6E9CF3404Q28086826-F9ABAD8E-BAD8-4209-9C3B-CD2EADD691EBQ30238730-279E01BF-235A-441A-B59C-AB61E76D4D65Q30425594-FBFE6D45-02D6-4C1E-82A9-95E2D3ED6F2BQ33592852-13D9C5E1-7D82-4094-A6D7-AADBE1A5A08AQ34407843-D434636C-C38F-4C76-8D5F-5D56B2B62FF9Q34478071-B5C6F6D6-ADF4-487D-A884-27D91362DFE6Q35034268-905627FA-C48A-4343-A7E8-7B598DC9B7A4Q35640998-88E4F684-3EA6-4B9B-8E49-40FE90B63E05Q35641234-FDAA571C-E451-4AAA-93FA-2AF3E426F8B7Q35685300-AF31E7B1-AA7E-4EE4-B3AD-D1333B4BCA0EQ36020766-DC4159B1-4800-4363-B110-67876F054C81Q36132925-1F9756A9-BD57-4F56-8B53-DD5FB0282884Q36276274-3276D96E-7389-4915-B439-08840D663C0AQ36397394-0FA57949-709D-48E5-B031-AEE12DF60217Q36414547-13FA9863-988C-4DD1-AC7A-C9C08A4C9855Q36444787-52885885-E789-42C3-A308-28EB238F128FQ36466846-A756943D-DAB3-466D-917F-D33BF8B1401DQ36469664-29573832-91CC-40DC-A06C-C82BCD3B858DQ36481483-91821455-80D8-4623-A7E7-E2F0CFBBE55AQ36736392-53BBED12-7E4A-47D6-8DFD-F5E2BC860472Q36760049-66D52383-B7AA-4F4D-8F1C-4C365A419EB3Q36785795-A4D714B5-B7B5-431D-945E-CAE7D005E6CAQ36888400-FB72B2FF-DD67-4C50-8C34-C9A890B9952CQ37069837-7AD1B513-F9ED-430A-9C36-E4E5FD649998Q37409244-2B3E0B3B-B1E5-42A6-B2B0-4329ADFB9BFBQ37551245-31A4FA60-F4CC-4686-A3C2-15C0035C355FQ38072056-6500CC76-F2CB-4B20-9B2F-CC72529C0BF5Q38747466-4E962213-056C-41C7-B5FC-5BF9FB04962EQ38811547-9821BBD4-3423-4B49-B7CD-6C8A0419B3C7Q39036775-83FA3DB6-179E-47BB-B04E-C47B37675623Q39108716-F1B03517-9B9C-4B90-A4F6-9444E6E8FE9FQ40088787-0EF9C690-9BC8-4178-86C3-9F0CFBF299C8Q40091554-375CDB6B-599A-4406-963A-81A31FADA48E
P2860
Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Selection pressure on HIV-1 en ...... he conserved CD4-binding site.
@ast
Selection pressure on HIV-1 en ...... he conserved CD4-binding site.
@en
type
label
Selection pressure on HIV-1 en ...... he conserved CD4-binding site.
@ast
Selection pressure on HIV-1 en ...... he conserved CD4-binding site.
@en
prefLabel
Selection pressure on HIV-1 en ...... he conserved CD4-binding site.
@ast
Selection pressure on HIV-1 en ...... he conserved CD4-binding site.
@en
P2093
P2860
P50
P356
P1433
P1476
Selection pressure on HIV-1 en ...... he conserved CD4-binding site.
@en
P2093
Charlene Wang
Hiromi Imamichi
James A Hoxie
Mark Connors
Nicole Doria-Rose
Richard T Wyatt
Sijy O'Dell
Xueling Wu
Zhongjia Yang
P2860
P304
P356
10.1128/JVI.07139-11
P407
P577
2012-03-14T00:00:00Z